

# ausrichter news

# Proin<sup>®</sup> newsletter

Number 51

## Urinary incontinence treatment in female and male dogs: a new treatment

Urinary incontinence [Ui] is an inconvenient disease for the dog owner and the household in which the dog lives. By the time of the onset of Ui, the dog is considered part of the family. Managing a dog with Ui is seen as an additional household task.

The smell of urine from a leaking dog is particularly unpleasant and unhealthy.

Dogs owners begin by first noticing the occasional dripping of urine from incontinent dogs. The dog's sleeping areas often become damp, moistened by the small amounts of urine voided. The first thought by the dog owner is an accident, but unfortunately incontinence usually continues and the frequency increases. Many dogs owners are unaware of a proven medical treatment available for their long-loved pet and companion, and for the management of urinary incontinence in both female and male dogs.

## Urinary incontinence in female dogs

The increased incidence of urinary incontinence has been linked to ovariectomy increasing with age, weight and hormone changes.


There are many studies on the increased incidence of Ui in spayed female dogs. Large dogs >25 kg are at an increased risk. The incidence of Ui in a number of pure breeds is also higher.

PROIN<sup>®</sup> administered orally at 2 mg/kg twice daily was effective for the control of urinary incontinence in a study of 180 days with owner satisfaction of 98%.<sup>4</sup>

**A positive side effect of PROIN<sup>®</sup> treatment was body weight loss (≥5%) in 24.8% of dogs treated.<sup>4</sup>**

## Use of Oestrogens in female dogs

Using oestrogens in dogs risk stimulating the development of pyometra and the potential for inducing aplastic anemia should be discussed with the owner. This should be weighed against the potential benefits. Alternative treatments with progesterone-receptor blockers, dopamine agonists, phenylpropanolamine or GnRH analogs for mis mating, pseudopregnancy, or hormonal urinary incontinence should be considered.<sup>5</sup>



1. Aaron, A.J., Eggleton, K.E., Power, S.C. & Holt, P.E. (1996) Urethral sphincter mechanism incompetence in male dogs: a retrospective analysis of 54 cases. *Vet. Rec.* 139, 542-546.  
2. Hall JL et al: Urinary incontinence in male dogs under primary veterinary care in England: <https://doi.org/10.1111/jsap.12951>; published 1 November 2018.  
3. McGreevy PD et al, Published: May 2, 2018 <https://doi.org/10.1371/journal.pone.0196284>. 4. (NADA 141 -324). 5. *Can Vet J.* 2009 Oct; 50(10): 1054-1058.

## Urinary incontinence in male dogs

Holt reported Ui in male dogs responded to treatment with phenylpropanolamine.<sup>1</sup>

A recent study in England of 109,428 male dogs attending 119 clinics identified 1072 dogs with Ui. The incidence of Ui increased with age (9-12 years) with no association to castration or bodyweight.<sup>2</sup>

**“The overall prevalence or urinary incontinence in male dogs was approximately 1%, which may be higher than expected given the sparsity of reports describing this problem. In contrast to bitches neutering and bodyweight were not associated with a greater incidence of urinary incontinence”<sup>2</sup>**

The percentage of ovariohysterectomy/castration of dogs in Australia has been reported:

Australia – 85% females and 77% males.<sup>3</sup>

There are very few reports of Ui in male dogs. A survey of male dogs in England in 2018 indicated an incidence of Ui of about 1%. Translation of this level of Ui to Australia dog population would suggest a number of male dogs with Ui as up to 200,000.

In male dogs there are a number of conditions that result in Ui: ie neurological, anatomical, and accident related injuries that do not respond to phenylpropanolamine treatment.

PROIN<sup>®</sup> Chewable Tablets are the only registered treatment of Ui in male dogs.

If the diagnosis is inconclusive a 7-10 days treatment with PROIN<sup>®</sup> 50 mg Chewable Tablets at 2 mg/kg b.i.d will indicate if the Ui will respond long term to treatment with PROIN<sup>®</sup>.

### PRODUCT INFORMATION

## PROIN<sup>®</sup> 50 mg Chewable Tablets

**For use in dogs (female and male) to control urinary incontinence associated with urethral sphincter hypotonus.**

### Composition

Phenylpropanolamine hydrochloride, 25 mg; 50 mg; 75 mg scored tablets. Specially formulated with liver flavouring – taste tested on dogs.

### Actions

Phenylpropanolamine is a sympathomimetic which acts by direct stimulation of the  $\alpha$ -adrenergic receptors in the smooth muscle of the internal urethral sphincter.

### Indication

PROIN<sup>®</sup> is indicated for control of urinary incontinence due to urethral sphincter hypotonus in female and male dogs.

### Contraindication

DO NOT USE in pregnant or lactation bitches.

### Precautions

Take care when treating animals with severe renal, hepatic insufficiencies or cardiovascular disease, diabetes mellitus, hyperadrenocorticism, glaucoma, hyperthyroidism or other metabolic diseases.

PROIN<sup>®</sup> treatment may be considered at 50% of the recommended dose and then slowly increased to a level at which urinary incontinence is controlled.

### Adverse reactions

In healthy dogs side effects were not observed when up to five times the recommended dose was administered.

### Interactions

Do not administer to dogs treated with non-selective monoamine oxidase inhibitors. Possible interactions should be considered when PROIN<sup>®</sup> is concurrently administered with sympathomimetics, anticholinergic drugs and tricyclic antidepressants.

### Overdosing

When overdosed phenylpropanolamine may produce excessive stimulation of the sympathetic nervous system; treatment of side effects should be symptomatic.

### Dosage and administration

Female and male dogs 2 mg/kg b.i.d (twice a day).

### Presentation

Chewable tablets scored – 25 mg, 50 mg, 75 mg in packs of 60 and 180 (not all tablets or pack sizes may be marketed).

A product of:

PRN Pharmacal, Pensacola FL 32514 USA

Distributed by:

Ausrichter Animal Health

APVMA Approval No.: 83535/108576

# ausrichter

Ausrichter Pty Ltd  
ABN 79 000 908 529

2/21 Chester Street, Camperdown NSW 2050

Telephone: (02) 9517 1166

Fax: (02) 9516 5810

Email: info@ausrichter.com

Animal Health Products

www.ausrichter.com